CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Outcomes of Critically Ill Children With Acute Lymphoblastic Leukemia and Cytokine Release Syndrome Due to Chimeric Antigen Receptor T Cell Therapy: US, Multicenter PICU, Cohort Database Study.
Outcomes of Critically Ill Children With Acute Lymphoblastic Leukemia and Cytokine Release Syndrome Due to Chimeric Antigen Receptor T Cell Therapy: US, Multicenter PICU, Cohort Database Study.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
PICU 中发生 CRS 的患者常接受高水平的支持治疗,且大多数患者存活至转出 PICU 及出院。有必要对严重 CRS 开展进一步的多中心研究,以指导循证实践。
细胞因子释放综合征(CRS)是与儿童急性淋巴细胞白血病(ALL)CAR-T 细胞治疗相关的潜在致死性毒性。因重度CRS导致危重病后的结局描述甚少。我们的目的是在一个多中心PICU的ALL合并CRS患者队列中描述危重病的结局。
多中心回顾性队列研究。21个PICU向Virtual Pediatric Systems, LLC提供数据(2020年1月至2021年12月)。患者:PICU中患有ALL或未分类白血病及CRS的患者。干预:无。测量与主要结果:我们识别出55例患者;34例(62%)年龄在12岁或以上,48例(87%)从医院住院病房收入,23例(42%)接受了晚期器官衰竭支持或监测。51例存活至PICU出院(93%),包括23例中19例(83%)接受了晚期器官衰竭支持或监测,定义为接受无创或有创通气、心肺复苏、体外膜氧合、连续肾脏替代治疗,或放置气管造口、动脉导管、血液透析导管或颅内导管。12例患者(22%)接受了有创通气,其中9例存活至PICU出院。4例接受连续肾脏替代治疗的患者中有2例存活至PICU出院,3例需要心肺复苏的患者中有1例存活至PICU出院。PICU存活者中PICU住院时间中位数为3.0天(四分位距,1.4-7.8天),接受晚期器官衰竭支持或监测者为7.8天(5.4-11.1),未存活者为7.2天(四分位距,2.9-14.7天)。在51例存活至PICU出院的患者中,48例(94%)存活至出院。
Cytokine release syndrome (CRS) is a potentially lethal toxicity associated with chimeric antigen receptor T cell therapy for pediatric acute lymphoblastic leukemia (ALL). Outcomes after critical illness due to severe CRS are poorly described. Our aim was to characterize critical illness outcomes across a multicenter cohort of PICU patients with ALL and CRS. DESIGN: Multicenter retrospective cohort study. SETTING: Twenty-one PICUs contributing data to Virtual Pediatric Systems, LLC (January 2020-December 2021). PATIENTS: PICU patients with ALL or unclassified leukemia and CRS. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: We identified 55 patients; 34 (62%) were 12 years or older, 48 (87%) were admitted from a hospital inpatient ward, and 23 (42%) received advanced organ failure support or monitoring. Fifty-one survived to PICU discharge (93%) including 19 of 23 (83%) who received advanced organ failure support or monitoring defined as receipt of noninvasive or invasive ventilation, cardiopulmonary resuscitation, extracorporeal membrane oxygenation, continuous renal replacement therapy, or placement of a tracheostomy, arterial catheter, hemodialysis catheter, or intracranial catheter. Twelve patients (22%) received invasive ventilation, nine of whom survived to PICU discharge. Two of four patients who received continuous renal replacement therapy and one of three patients who required cardiopulmonary resuscitation survived to PICU discharge. Lengths of PICU stay were median 3.0 days (interquartile range, 1.4-7.8 d) among PICU survivors, 7.8 (5.4-11.1) among those receiving advanced organ failure support or monitoring, and 7.2 days (interquartile range, 2.9-14.7 d) among nonsurvivors. Of the 51 patients who survived to PICU discharge, 48 (94%) survived the hospitalization.
PICU patients with CRS frequently received a high level of support, and the majority survived their PICU stay and hospitalization. Additional multicenter investigations of severe CRS are necessary to inform evidence-based practice.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。